Premium
The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response
Author(s) -
Charatcharoenwitthaya Phunchai,
Pongpaibul Ananya,
Kaosombatwattana Uayporn,
Bhanthumkomol Patommatat,
Bandidniyama Wimolrak,
Pausawasdi thalee,
Tanwandee Tawesak
Publication year - 2017
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.13271
Subject(s) - steatohepatitis , medicine , steatosis , gastroenterology , odds ratio , fatty liver , hepatitis b , disease
Background & Aims The clinical significance of steatohepatitis in chronic hepatitis B remains unclear. This study aimed to determine the prevalence and risk factors for steatohepatitis in chronic hepatitis B, and to determine its correlation with liver fibrosis and response to antiviral therapy. Methods Liver histopathology of 256 consecutive chronic hepatitis B patients with serum hepatitis B virus DNA >2000 IU /mL were analysed with clinical and laboratory characteristics. Virological and biochemical responses were prospectively assessed in the 112 patients treated with antiviral monotherapy. Results Hepatic steatosis was observed in 38% of the entire cohort, and steatohepatitis was diagnosed in 18% of patients with hepatic steatosis according to Brunt's classification. The presence of steatohepatitis was associated with overweight/obese (odds ratio, 5.99; 95% CI , 1.32‐27.2) and hypertriglyceridaemia (odds ratio, 2.95; 95% CI , 1.07‐8.15). None of the viral characteristics including HB eAg status, genotypes and viraemia levels was associated with the presence of steatohepatitis. Steatohepatitis was an independent predictor of significant fibrosis (odds ratio, 10.0; 95% CI , 2.08‐48.5) and advanced fibrosis (odds ratio, 3.45; 95% CI , 1.11‐10.7) after adjusting for viraemia levels and features of the metabolic syndrome. The rates of suppression of serum hepatitis B virus DNA <20 IU /mL combined with aminotransferase normalization at week 48 of antiviral therapy were not different between the steatohepatitis and non‐steatohepatitis groups (43% vs 53%; P =.475). Conclusions Steatohepatitis is not uncommon in chronic hepatitis B patients. It is associated with metabolic syndrome but not viral factor. This study demonstrates that steatohepatitis is related to the severity of liver fibrosis but it does not affect response to antiviral therapy.